Janssen Biotech, Inc.

New York University

Genmab A+s

Mark Chiu

Paul Parren

Janine Schuurman

Sheri Moores

Joost Neijssen

Brian Whitaker

Di Zhang

William Strohl

Victor J Torres

Randall J Brezski

Adam Zwolak

Anthony A Armstrong

Peter T Buckley

Anthony S Lynch

Keri Dorn

Michelle Kinder

Aran Frank Labrijn

Joyce Meesters

Thomas C Nesspor

Matthew Bunce

Joyce I Meesters

Bispecific EGFR/c-Met antibodies and methods of making and using the molecules.

Bispecific EGFR/c-Met antibodies

The present invention relates to engineered anti-TNFR superfamily member antibodies having enhanced agonistic activity and methods of using them.

FC engineered anti-TNFR superfamily member antibodies having enhanced agonistic activity and methods of using them

The present invention relates to engineered multispecific antibodies and other multimeric proteins with asymmetrical CH2-CH3 region mutations and methods of making and using them.

Engineered multispecific antibodies and other multimeric proteins with asymmetrical CH2-CH3 region mutations

FN3 domains that specifically bind Fc&#x3b3;RII, their conjugates and antibody fusions, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making and using them.

Fc &#x3b3;  RIII binding fibronectin type III domains, their conjugates and multispecific molecules comprising them

Novel rodent bispecific heterodimeric proteins, such as rodent bispecific antibodies, in vitro method for producing such, and uses thereof.

Rodent bispecific heterodimeric proteins

The present invention relates to engineered antibodies and other Fc-domain containing molecules with enhanced agonism and effector functions.

Engineered antibodies and other Fc-domain containing molecules with enhanced agonism and effector functions

The present application generally relates to multi-specific molecules that bind to multiple bacterial virulence factors, methods for producing these binding molecules, and the use of these binding molecules to treat bacterial infections. In particular, the binding molecules comprise at least two binding domains, preferably an antibody or antibody fragment and an alternative scaffold. The first binding domain is capable of binding to a glycosylated staphylococcal surface protein, preferably an SDR-containing protein. The second binding domain is capable of binding to a staphylococcal leukotoxin, preferably LukAB, LukD or LukE. These multi-specific binding compounds have killing activity against staphylococci and, thus, can be used in the treatment and/or amelioration of ainfection, including methicillin-resistant

Compositions and methods for phagocyte delivery of anti-staphylococcal agents

Growing community of inventors

Spring House, PA, United States of America

Mark Chiu